Orders from 100 GBP Free delivery from 205 GBP Ready for pickup dead drop: collect in 5 min

Substances · Phenethylamine derivatives

5-MAPB

C12H15NO CAS 1354631-77-8 Analytical reference material — not for human consumption
Preferred name
5-MAPB
IUPAC name
1-(1-benzofuran-5-yl)-N-methylpropan-2-amine
Parent CAS number (reference)
1354631-77-8
Molecular formula
C12H15NO
Molecular weight
189.25 g/mol
InChIKey
ZOVRTIPCNFERHY-UHFFFAOYSA-N
PubChem
CID 102336592
Source
PubChem
Verified synonyms & catalog abbreviations
5-(2-Methylaminopropyl)benzofuran 5MAPB 5 MAPB

Matching Listings in This Store's Catalog

Verified Neurochemical & Toxicological Intelligence

5-MAPB

Entactogen (serotonin-dominant monoamine releaser) 5-Substituted benzofuran (N-methyl)
Verified PubChem & CAS Identity C12H15NO · CAS 1354631-77-8 · CID 102336592
Calibrated Physical Form Pure Crystalline / Analytical Powder (≥98%)
≥98% Analytical Purity Verified 189.25 g/mol
Peer-Reviewed & Agency Citations 2 · verified sources

Receptor Telemetry & Mechanism of Action

DAT Dopaminergic Signaling Primary
NET Noradrenergic Signaling Active
SERT Serotonergic Signaling Variable

5-MAPB is the N-methyl analogue of 5-APB and a benzofuran entactogen. It releases serotonin with dopamine and norepinephrine and feels closer to MDMA than 6-APB does: warmer, less psychedelic, and less openly stimulating. The 5-position oxygen is associated with a more stimulating balance than the 6-position, but 5-MAPB is still a serotonin releaser first. PsychonautWiki notes that the hydrochloride is substantially more potent by mass than the succinate, so a milligram of one salt is not a milligram of the other.

Biotransformation & Active Metabolites

Not a prodrug of MDMA. The benzofuran itself is the releaser. Salt form changes the mass that must be weighed. The freebase formula C12H15NO (189.25 g/mol) is the parent amine, not the succinate.

Temporal Pharmacokinetics

Warm, MDMA-like entactogen with less visual and psychedelic overlay than 6-APB and a meaningful next-day flatness.

  1. Onset 20–60 minutes
  2. Peak Window 2–4 hours
  3. Total Window 5–8 hours
  4. Residual / Half-Life After-effects 6–48 hours of low mood, fatigue, and insomnia. That tail is serotonergic depletion, not a sign to redose.

Threshold 20 mg, light 40–60 mg, common 60–80 mg, strong 80–100 mg, heavy above 100 mg on the PsychonautWiki oral sheet. Come-up is 45–90 minutes. repeated exposure because the first hour felt mild is the usual overshoot, and a succinate-to-hydrochloride swap makes the same number too strong.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
20 mg
Cognitive & Sensory

A soft mood lift without a roll.

Somatic & Autonomic

Light body warmth.

Light
40–60 mg
Cognitive & Sensory

Gentle empathy, music enhancement, and mild stimulation.

Somatic & Autonomic

Jaw tension, appetite loss, and pupil dilation starting.

Common Reference
60–80 mg
Cognitive & Sensory

Clear emotional openness, tactile enhancement, and mood elevation with less 'push' than MDMA.

Somatic & Autonomic

Bruxism, sweating, tachycardia, and a warm body load.

Strong
80–100 mg
Cognitive & Sensory

Intense entactogenic state, some visual drifting, and less additional warmth per extra milligram.

Somatic & Autonomic

Hyperthermia risk, nausea, strong bruxism, and a heavier cardiovascular load.

Heavy / Toxic Zone
100 mg+
Cognitive & Sensory

Overwhelmed, anxious, or confused rather than more empathic. Stacking a second releaser here is a serotonin emergency.

Somatic & Autonomic

Severe hyperthermia, hypertension, and seizures with tramadol, MAOIs, or MDMA.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

MAOIs (phenelzine, tranylcypromine, moclobemide, harmala alkaloids)

Blocking monoamine breakdown while a releaser or a catecholamine uptake inhibitor is active can produce a hypertensive crisis and, for the serotonergic members, serotonin toxicity.

MDMA, 4-FA, 4-FMA, 6-APB, MDA, and other serotonin releasers

5-MAPB is already a serotonin releaser. A second releaser is the serotonin-syndrome combination.

Tramadol and 5-HTP

Extra serotonergic load and, for tramadol, a lower seizure threshold.

Elevated Hazard — Avoid

Stimulants, cocaine, and 25x-NBOMe

Cardiovascular strain and, with NBOMes, seizures and vasospasm.

Alcohol and dehydrating environments

Mask intoxication and raise hyperthermia and hyponatremia risk, the same pattern as MDMA.

Caution / Receptor Attenuation

SSRIs and SNRIs

Often blunt the roll and still leave the cardiovascular load. They do not make an MAOI or MDMA combination safe.

A different salt of the same name

Hydrochloride weighs less per active molecule than succinate. Using a hydrochloride mass with a succinate habit overshoots.

Structural Isomer & Sibling Comparison

5-MAPB is the shorter, more MDMA-like benzofuran: common 60–80 mg, 5–8 hours, less psychedelic than 6-APB. 6-APB common is 60–90 mg but lasts 7–10 hours, comes up for 1–2 hours, and carries a stronger 5-HT2B cardiotoxicity concern with frequent use. 6-MAPB is the N-methyl-6 analogue; TripSit places its common oral band at 40–80 mg. All three share the 'never stack releasers' rule. 5-MAPB is not 5-MeO-MiPT and not 4-FA.

Physicochemical Stability & Storage

Form: White, off-white, or pale tan crystalline powder, shards, or clumps as the hydrochloride or another salt. Not a plant blend. · Hydrochloride salts dissolve in water and alcohols. Succinate salts of the benzofurans also dissolve in water but contain less active amine per milligram.

Airtight, cool, dry, and dark. Some salts are hygroscopic and clump. A clump is not a reason to guess the mass.

Cross-Tolerance & Dependence Profile

Serotonergic tolerance is the limiting factor. The warm phase fades with closely spaced uses while stimulation and side effects remain. Cross-tolerance with MDMA, 4-FA, and the other benzofurans. PsychonautWiki's 6-APB sheet describes a multi-week return to baseline for that sibling; 5-MAPB deserves the same spacing. The crash is low mood and fatigue, not opioid withdrawal. Psychological urge to redose during the 45–90 minute come-up is the acute hazard.

Comprehensive Analytical & Toxicological Monograph

5-MAPB (1-(1-benzofuran-5-yl)-N-methylpropan-2-amine; CAS 1354631-77-8, PubChem CID 102336592) is a 5-substituted benzofuran entactogen supplied as pure powder or crystals (freebase parent C12H15NO, 189.25 g/mol). It is the N-methyl analogue of 5-APB and a serotonin-dominant releaser, warmer and less psychedelic than 6-APB. PsychonautWiki oral bands are threshold 20 mg, light 40–60 mg, common 60–80 mg, strong 80–100 mg, and heavy above 100 mg, over 5–8 hours with a 45–90 minute come-up. The hydrochloride is more potent by mass than the succinate, so the weighed number depends on the salt. After-effects of low mood can last up to two days. Do not combine with MAOIs, MDMA, 4-FA, other releasers, or tramadol.

Chemical Architecture & Structural Profile

5-MAPB (1-(1-benzofuran-5-yl)-N-methylpropan-2-amine) is a reference compound belonging to the Phenethylamine derivatives class, characterized by the molecular formula C12H15NO and a molar mass of 189.25 g/mol. The parent molecule is indexed under CAS registry number 1354631-77-8 and in the NCBI PubChem database as CID 102336592 (Standard InChIKey: ZOVRTIPCNFERHY-UHFFFAOYSA-N). This molecule shares its empirical formula (C12H15NO) with positional or structural isomers; unambiguous analytical identification requires matching the full IUPAC structure, CAS number (1354631-77-8), and spectroscopic profile.

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), 5-MAPB is indexed within the Substituted amphetamines, Substituted benzofurans structural group. Toxicological notes (PsychonautWiki): exact toxic threshold is unknown. Dependence liability (PsychonautWiki): moderately addictive with a high potential for abuse. Documented cross-tolerance class: dopamine, stimulant. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations

Documented Contraindications & Interactions

High-risk / Dangerous combinations

Unsafe combinations (elevated hazard)

Uncertain combinations (caution advised)